M
Marie Scully
Researcher at National Institute for Health Research
Publications - 22
Citations - 683
Marie Scully is an academic researcher from National Institute for Health Research. The author has contributed to research in topics: Thrombotic microangiopathy & Thrombotic thrombocytopenic purpura. The author has an hindex of 9, co-authored 22 publications receiving 359 citations. Previous affiliations of Marie Scully include University College Hospital & University College London Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Eric Rondeau,Marie Scully,Gema Ariceta,Thomas D. Barbour,Spero R. Cataland,Nils Heyne,Yoshitaka Miyakawa,Stephan Ortiz,Eugene Swenson,Marc Vallee,Sung-Soo Yoon,David J. Kavanagh,Hermann Haller,Sunil Babu,Nilufer Broeders,Nicole Lietar,Fiona G. Brown,Philip Campbell,Paramit Chowdhury,Theo Kasimatis,Lino Cirami,Leonardo Caroti,Guilia Antognoli,Yahsou Delmas,Vladimir A. Dobronravov,Anja Gaeckler,Cyril Garrouste,Gregory Greenwood,Siân V. Griffin,Chiu-Ching Huang,I-Ru Chen,Susan Huang,Jin Seok Kim,Gaetano La Manna,Giorgia Comai,Maria Cappuccilli,Moglie Le Quintrec,Guillaume Jeantet,Iino Fumie,Yosu Luque,Jan Menne,Johan Morelle,Eric Goffin,Anja Muhlfeld,Shashi K. Nagaraj,Gowthami M. Arepally,Doyeun Oh,Masayoshi Okumi,Manuel Praga Terente,Elena Gutierréz,Paola Rodriguez,François Provôt,Ulf Schönermarck,Michael Fischereder,Natalia Ramos Terrada,Barbara Seitz-Polski,Guillaume Favre,Sonia Boyer-Suavet,Maria Vinogradova,Tatiana Kirsanova,Edwin K.S. Wong +60 more
TL;DR: Treatment with ravulizumab once every eight weeks resulted in rapidly improved hematologic and renal endpoints with no unexpected adverse events in adults with atypical hemolytic uremic syndrome.
Journal ArticleDOI
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.
Franz Schaefer,Gianluigi Ardissino,Gema Ariceta,Fadi Fakhouri,Marie Scully,Nicole M. Isbel,Åsa Lommelé,Varant Kupelian,Christoph Gasteyger,Larry A. Greenbaum,Sally Johnson,Masayo Ogawa,Christoph Licht,Johan Vande Walle,Véronique Frémeaux-Bacchi,M. Blasco,Donata Cresseri,Galina Generolova,Nicholas J.A. Webb,Patricia Hirt-Minkowski,Natalya Lvovna Kozlovskaya,Daniel Landau,Anne-Laure Lapeyraque,Chantal Loirat,Christoph J. Mache,Michal Malina,Leena Martola,Annick Massart,Eric Rondeau,Andrew M. Siedlecki,Lisa Sartz +30 more
TL;DR: Real-world results provide novel insights regarding phenotypic variables and genotypes on the clinical manifestation and progression of aHUS as well as the genetic background of 851 patients in the registry, prior to eculizumab treatment.
Journal ArticleDOI
Characterization and treatment of congenital thrombotic thrombocytopenic purpura
Ferras Alwan,Chiara Vendramin,Ri Liesner,Amanda Clark,William Lester,Tina Dutt,William Thomas,Richard Gooding,Tina Biss,Henry G. Watson,Nichola Cooper,Rachel Rayment,Tanya Cranfield,Joost J. van Veen,Quentin A. Hill,Sarah Davis,Jayashree Motwani,Neha Bhatnagar,Nicole Priddee,Marianna David,Maeve P. Crowley,Jayanthi Alamelu,Hamish Lyall,John-Paul Westwood,Mari Thomas,Mari Thomas,Marie Scully,Marie Scully +27 more
TL;DR: In conclusion, prespacer mutations are associated with earlier development of cTTP symptoms and decreases the risk of end-organ damage such as ischemic stroke and resolved previously unrecognized symptoms in patients with nonovert disease.
Journal ArticleDOI
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.
John-Paul Westwood,Mari Thomas,Ferras Alwan,Vickie McDonald,Sylvia Benjamin,William Lester,Gillian C. Lowe,Tina Dutt,Quentin A. Hill,Marie Scully +9 more
TL;DR: Rituximab therapy is effective as prophylaxis for normalizing ADAMTS13 and is an additional measure for preventing acute TTP relapses in patients with immune TTP.
Journal ArticleDOI
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura
Ferras Alwan,Chiara Vendramin,Karen Vanhoorelbeke,Katy Langley,Vickie McDonald,Steve Austin,Amanda Clark,William Lester,Richard Gooding,Tina T. Biss,Tina Dutt,Nichola Cooper,Oliver Chapman,Tanya Cranfield,K. Douglas,Henry G. Watson,J. J. van Veen,Keith Sibson,William Thomas,Lynn Manson,Quentin A. Hill,Sylvia Benjamin,Debra Ellis,John-Paul Westwood,Mari Thomas,Marie Scully +25 more
TL;DR: It is concluded that both anti-ADAMTS13 IgG antibody and ADAMts13 antigen levels correlate with outcome in TTP with increased cardiac and neurological involvement and increased mortality.